Skip to content
10-K

Annual Report

SPYRE THERAPEUTICS, INC. SYRE

0001636282-26-000020

← back to feed
Filed
Feb 19, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 12, 2026 78.54M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$169.25M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$157.41M
Cash And Equivalents FY 2025 · Dec 31, 2025 $85.72M
Cash And Equivalents FY 2025 · Dec 31, 2024 $89.42M
Stockholders Equity FY 2025 · Dec 31, 2025 $715.24M
Stockholders Equity FY 2025 · Dec 31, 2024 $517.8M
Current Liabilities FY 2025 · Dec 31, 2025 $58.69M
Current Liabilities FY 2025 · Dec 31, 2024 $54.06M
Total Liabilities FY 2025 · Dec 31, 2025 $62.55M
Total Liabilities FY 2025 · Dec 31, 2024 $90.68M
Current Assets FY 2025 · Dec 31, 2025 $777.78M
Current Assets FY 2025 · Dec 31, 2024 $608.47M
Total Assets FY 2025 · Dec 31, 2025 $777.78M
Total Assets FY 2025 · Dec 31, 2024 $608.48M
Sga Expense FY 2025 · Dec 31, 2025 $47.91M
Sga Expense FY 2025 · Dec 31, 2024 $45.78M
Net Income FY 2025 · Dec 31, 2025 −$155.2M
Net Income FY 2025 · Dec 31, 2024 −$208.02M
Operating Income FY 2025 · Dec 31, 2025 −$209.56M
Operating Income FY 2025 · Dec 31, 2024 −$208.57M
Revenue FY 2025 · Dec 31, 2025 $0
Revenue FY 2025 · Dec 31, 2024 $0